Loading...
•
Dec 31, 2019
Exact Sciences Q4 2019 Earnings Report
Generated revenue of $295.6 million, including Screening revenue of $229M and Precision Oncology revenue of $66M.
Key Takeaways
Exact Sciences Corp. reported a strong fourth quarter with a total revenue of $295.6 million and a net income of $77.9 million. Screening revenue increased by 60%, and Precision Oncology revenue was $66.2 million. The company's adjusted EBITDA was $9.7 million.
Total revenue was $295.6 million.
Screening revenue was $229.4 million, an increase of 60 percent.
Precision Oncology revenue was $66.2 million for the period Nov. 8, 2019 through Dec. 31, 2019.
Net income was $77.9 million, or $0.54 per diluted share.
Exact Sciences
Exact Sciences
Exact Sciences Revenue by Segment
Revenue by Segment
Screening Revenue
CapyFin.comPrecision Oncology Revenue
CapyFin.com Forward Guidance
The Company anticipates revenue of $1.61-$1.645 billion during 2020, including Screening revenue of $1.125-$1.15 billion and Precision Oncology revenue of $485-$495 million.
Revenue & Expenses
Visualization of income flow from segment revenue to net income